R. Wills

Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.

D. Manallack, W. Pitt, J. Montana, 2001, Bioorganic & medicinal chemistry letters.

In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.

C. Löwik, A. Baxter, G. van der Pluijm, 2003, The American journal of pathology.

The design, synthesis, and evaluation of novel conformationally rigid analogues of sialyl Lewisx

D. Manallack, J. Montana, R. Hubbard, 1998 .

Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease.

A. Baxter, J. Bird, R. Greenwald, 2002, Journal of periodontal research.

A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo

M. Teixeira, N. Cooper, R. Gristwood, 1999, British journal of pharmacology.

Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.

J. Fargnoli, R. Talbott, R. Kramer, 2001, Cancer research.